Scope for guideline update (starting 2025) MASLD (GID-NG10434)
"India's Biocon developing its own version of Wegovy, clinical trial likely next year"
The GLP-1-RA group was associated with reduction in acetazolamide dosage at M6 (\(\beta\)= 288.15, 95% CI 553.09, 23.22, p = 0.03), which did not withstand the adjustment for weight loss
According to Irish health data: Approximately 60% of adults in Ireland are overweight or obese Around 1 in 4 adults meet the criteria for obesity Childhood overweight and obesity rates remain a significant concern Rates continue to trend upward over time Obesity is now one of the leading modifiable risk factors contributing to: Type 2 diabetes Hypertension Cardiovascular disease Stroke Certain cancers Osteoarthritis Fatty liver disease From a healthcare system perspective, obesity contributes significantly to long-term healthcare expenditure
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
This reference material is supplied as a lyophilised powder for in-vitro laboratory and analytical research use only
